Clinical Research
Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial
Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker
Praxis touts ‘best-in-disease’ epilepsy data, but shares dip
Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market
Viome and Scripps Initiate AI-Powered At-Home RNA Test for Early Colon Cancer Risk Detection
Viome; Scripps Research; AI-powered diagnostics; RNA test; at-home colon cancer screening; colon polyps; clinical study; microbiome; early cancer detection
Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS
Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug
Future in doubt as Opthea’s AMD drug flunks first pivotal study
Opthea ‘s, Opthea, Future, Clinical Research
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome
Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Neumora’s Navacaprant Fails to Meet Expectations in First Phase 3 Trial for Major Depressive Disorder
Neumora Therapeutics, Navacaprant, Major Depressive Disorder, Phase 3 Trial, KOASTAL-1 Study
Javara Undergoes Restructuring, Lays Off Staff Amidst Industry-Wide Challenges
Javara, layoffs, restructuring, clinical research, biopharma industry challenges